Skip to main content
Premium Trial:

Request an Annual Quote

OncoMethylome's First-Half Revenues Fall 17 Percent

NEW YORK (GenomeWeb News) – OncoMethylome today reported that its first-half 2009 revenues fell 17 percent due to one-time up-front fees and milestone payments in 2008 that were not repeated in 2009.

The Liege, Belgium-based molecular diagnostics firm reported revenues of €1.3 million ($1.9 million) for the first six months of 2009, compared to revenues of €1.5 million for the first half of 2008.

Its net loss for the period was €6.3 million, or €.48 per share, versus a net loss of €5.7 million, or €.48 per share, for the first half of 2008.

OncoMethylome's R&D expenses declined to €5.6 million from €5.8 million year over year, while its SG&A spending increased to €2.1 million from €1.8 million.

"Most of the R&D efforts in H1 2009 were focused on enhancing the ease of use of the blood-based colorectal cancer screening test for commercial purposes and validating the test on ever-increasing clinical sample sets," Herman Spolders, CEO of OncoMethylome, said in a statement.

OncoMethylome had cash and cash equivalents of €23.7 million as of June 30.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.